Benefits to community and social organizations: If found that APRI and FIB-
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients who underwent successful LSM using TE (from transient elastography database) in 11 participated centers from January 1st, 2009 – August 31st, 2017 whose indications of fibrosis assessment were one of the following; 1)Chronic HBV infection (CHB): defined as HBsAg+ for at least six months, who were not treated with antiviral agent(s) or interferon treatment at the time of LSM. 2)Chronic HCV infection (CHC): defined as antiHCV+ and detectable viremia by HCV RNA, who were not treated with Peginterferon+Ribavirin or direct antiviral agents (DAA) at the time of LSM. 3)NAFLD: defined as hepatic steatosis detected by imaging and/or evidence of steatohepatitis from liver histology plus history of alcohol intake <20 gm/day and HBsAg- antiHCV-
Exclusion criteria
Exclusion criteria: 1) Chronic hepatitis patients from other causes other than CHB, CHC, and NAFLD as described above 2) Patients with co-infection with human immunodeficiency virus (HIV), or HBV/HCV co-infection 3) No available laboratory results of AST, ALT, platelet level within 3 months of LSM 4) Patients with coexisted diseases of either active hemolysis at time of AST/ALT measurement, immune mediated thrombocytopenia, or hematologic malignancies 5) Patients with AST or ALT > 5 times above ULN 6) The subsequent TE measurement(s) in the same patients after the first enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fibrosis stage 3 year Outcome measurement is fibrosis stage using TE as reference standard, which were validated in numero | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Khonkaen University